Recent Updates
Recently added Catalysts
EW Negative Sentiment Score: 25/100

EDWARDS LIFESCIENCES CORPORATION (NYSE: EW) INVESTOR ALERT: Investors With Large Losses in Edwards Lifesciences Corporation Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Key Takeaway: A securities class action lawsuit has been filed against Edwards Lifesciences Corporation on behalf of investors who acquired its securities between February 6, 2024, and July 24, 2024. The lawsuit alleges that the company made false representations concerning its Transcatheter Aortic Valve Replacement platform and demand in lower-penetrated markets. Investors are encouraged to contact Bernstein Liebhard LLP to discuss their rights and the possibility of serving as lead plaintiffs. The law firm operates on a contingency fee basis, meaning shareholders incur no upfront costs.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against Edwards Lifesciences Corporation.
  • Claims of misrepresentations regarding the company's business strategy.
  • Investor losses reported related to the company's share performance.
  • Potential legal liabilities could impact the company's financial standing.

Full Press Release Details

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Edwards Lifesciences Corporation (“Edwards” or the “Company”) (NYSE: EW) between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”).
For more information, submit a form at Edwards Lifesciences Corporation Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030.
According to the lawsuit, Edwards made misrepresentations concerning, among other things, the Company’s strong commitment to the Transcatheter Aortic Valve Replacement platform, confidence in its ability to capitalize on a subset of untreated patients through scaling of its various patient activation activities, and continued claims of significant demand in allegedly lower-penetrated markets.
If you wish to serve as lead plaintiff for the Class, you must file papers by December 13, 2024. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2024 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

edwards lifesciences corp
class action lawsuit

Frequently Asked Questions

What is the Edwards Lifesciences class action about?

The lawsuit claims Edwards misrepresented its commitment to the Transcatheter Aortic Valve Replacement platform.

What is the deadline to serve as lead plaintiff?

Papers must be filed by December 13, 2024, to serve as lead plaintiff.

Do investors need to pay fees for representation?

All representation is on a contingency fee basis, meaning no fees are required upfront.

How can I contact Bernstein Liebhard LLP for more info?

You can email Peter Allocco or call them at (212) 951-2030 for more information.

What is Bernstein Liebhard LLP's track record?

Since 1993, they have recovered over $3.5 billion for clients and represented major pension funds.

Last updated: Oct 16, 2024